Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...
Upcoming Anticipated Clinical Milestones AMPLIFY-201: Provide updated RFS and OS data in an oral presentation at the 2024 ESMO Immuno-Oncology Congress, taking place from December 11-13, 2024, in ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Massive revenue growth, surging margins, and groundbreaking cancer breakthroughs--Natera's unstoppable rise is turning heads ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...
New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback